Total Valuation
Jeil Pharmaceutical Co. Ltd. has a market cap or net worth of ₩134.50B. The enterprise value is ―.
Market Cap₩134.50B
Enterprise Value―
Share Statistics
Jeil Pharmaceutical Co. Ltd. has 14,704,872 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding14,704,872
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Jeil Pharmaceutical Co. Ltd.’s return on equity (ROE) is 0.11 and return on invested capital (ROIC) is 5.16%.
Return on Equity (ROE)0.11
Return on Assets (ROA)0.05
Return on Invested Capital (ROIC)5.16%
Return on Capital Employed (ROCE)0.08
Revenue Per Employee582.06M
Profits Per Employee24.03M
Employee Count973
Asset Turnover1.11
Inventory Turnover3.43
Valuation Ratios
The current PE Ratio of Jeil Pharmaceutical Co. Ltd. is 4.8. Jeil Pharmaceutical Co. Ltd.’s PEG ratio is -0.05.
PE Ratio4.8
PS Ratio0.39
PB Ratio1.06
Price to Fair Value1.06
Price to FCF-16.24
Price to Operating Cash Flow17.79
PEG Ratio-0.05
Income Statement
In the last 12 months, Jeil Pharmaceutical Co. Ltd. had revenue of 566.34B and earned 23.38B in profits. Earnings per share was 1.60K.
Revenue566.34B
Gross Profit208.38B
Operating Income20.33B
Pretax Income34.95B
Net Income23.38B
EBITDA32.65B
Earnings Per Share (EPS)1.60K
Cash Flow
In the last 12 months, operating cash flow was 7.75B and capital expenditures -10.22B, giving a free cash flow of -2.47B billion.
Operating Cash Flow7.75B
Free Cash Flow-2.47B
Free Cash Flow per Share-167.75
Dividends & Yields
Jeil Pharmaceutical Co. Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.29
52-Week Price Change-30.25%
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)―
Average Volume (3m)20.63K
Important Dates
Jeil Pharmaceutical Co. Ltd. upcoming earnings date is Aug 7, 2026, TBA (Confirmed).
Last Earnings DateMay 15, 2026
Next Earnings DateAug 7, 2026
Ex-Dividend Date―
Financial Position
Jeil Pharmaceutical Co. Ltd. as a current ratio of 1.29, with Debt / Equity ratio of 45.66%
Current Ratio1.29
Quick Ratio0.85
Debt to Market Cap0.41
Net Debt to EBITDA1.36
Interest Coverage Ratio4.63
Taxes
In the past 12 months, Jeil Pharmaceutical Co. Ltd. has paid 2.95B in taxes.
Income Tax2.95B
Effective Tax Rate0.08
Enterprise Valuation
Jeil Pharmaceutical Co. Ltd. EV to EBITDA ratio is 8.19, with an EV/FCF ratio of -19.48.
EV to Sales0.47
EV to EBITDA8.19
EV to Free Cash Flow-19.48
EV to Operating Cash Flow-46.98
Balance Sheet
Jeil Pharmaceutical Co. Ltd. has ₩66.96B in cash and marketable securities with ₩97.38B in debt, giving a net cash position of -₩30.42B billion.
Cash & Marketable Securities₩66.96B
Total Debt₩97.38B
Net Cash-₩30.42B
Net Cash Per Share-₩2.07K
Tangible Book Value Per Share₩16.02K
Margins
Gross margin is 38.67%, with operating margin of 3.59%, and net profit margin of 4.13%.
Gross Margin38.67%
Operating Margin3.59%
Pretax Margin6.17%
Net Profit Margin4.13%
EBITDA Margin5.76%
EBIT Margin3.59%
Analyst Forecast
The average price target for Jeil Pharmaceutical Co. Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-23.33%
EPS Growth Forecast―